Inhibitors of Staphylococcus aureus NaMN adenylyltransferase NadD

金黄色葡萄球菌 NaMN 腺苷酸转移酶 NadD 抑制剂

• 批准号: 8262600
• 负责人: ANDREI L OSTERMAN
• 金额: $ 4.88万
• 依托单位: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-01-15 至 2013-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8262600
• 关键词: Active Sites; Address; Affinity; Anabolism; Anti-Bacterial Agents; Antibiotic Resistance; Antibiotics; Bacillus anthracis; Bacteria; Biogenesis; Biological Assay; Categories; Cephalosporins; Chemicals; Comparative Genomic Analysis; Complex; Computer Simulation; Development; Drug resistance; Enzymes; Escherichia coli; Essential Genes; Family; Family member; Future; Genes; Glutamate-ammonia-ligase adenylyltransferase; Goals; Gram-Negative Bacteria; Gram-Positive Bacteria; Growth; Hospitals; Human; In Vitro; Incidence; Infection; Inhibitory Concentration 50; Kinetics; Lead; Libraries; Metabolism; Methods; Modeling; Molecular Probes; Multi-Drug Resistance; National Institute of Allergy and Infectious Disease; Nicotinamide adenine dinucleotide; Nicotinate-nucleotide adenylyltransferase; Nosocomial Infections; Oxidation-Reduction; Pathway interactions; Penicillins; Property; Public Health; Recombinants; Reporting; Research Personnel; Resistance; Resort; Risk Factors; Screening procedure; Source; Staging; Staphylococcus aureus; Testing; Validation; Vancomycin; Work; analog; antimicrobial drug; base; cofactor; combat; comparative genomics; counterscreen; falls; functional genomics; high throughput screening; improved; in vitro Assay; inhibitor/antagonist; methicillin resistant Staphylococcus aureus; nicotinate mononucleotide; novel; pathogen; prototype; resistant strain; small molecule; tool

DESCRIPTION (provided by applicant): The rapid spread of multidrug-resistant strains of common bacteria pathogens pose a significant threat to public health, calling for an accelerated effort to develop novel antibiotics acting on previously unexplored targets. Most notably, many strains of Staphylococcus aureus, a major source of infections in hospitals, are resistant to commonly used antibiotics. Comparative genomics analysis and gene essentiality studies implicated nicotinic acid mononucleotide (NaMN) adenylyltransferase of the NadD family, the key indispensable enzyme in NAD biogenesis of most bacteria (including S. aureus), as a prominent target for the development of novel antimicrobial agents. In previous studies, first, small molecule inhibitors of NadD enzymes from representative gram-positive and gram-negative bacteria were identified, and then their on- target antibacterial activity was confirmed. Some of the identified compounds also showed strong inhibitory activity against S. aureus NadD enzyme. These results provided validation of the NadD target and set the stage for searching for new inhibitors with substantially improved affinity, selectivity, and antibacterial properties. This goal would be addressed in the proposed project by pursuing the following specific aims: (I) screen the MLPCN small molecule compound library and perform hit optimization to identify high-affinity inhibitors of S. aureus NadD enzyme (with IC50 d1 microM); (II) test confirmed hits by secondary assays and in the counter screen against is functional but structurally distinct human enzyme; (III) assess antibacterial properties and kinetic mechanisms of selected nominated probes. The feasibility of the proposed project is supported by the availability of the pure recombinant target enzyme as well as HTS assay methods developed in preliminary studies. Selected best inhibitors will be used in future work as molecular probes to further explore NAD biosynthesis as a target pathway for the development of novel antibiotics.

描述(由申请人提供)：常见细菌病原体的多重耐药菌株的快速传播对公众健康构成了重大威胁，要求加快努力开发针对以前未探索的目标的新型抗生素。最值得注意的是，作为医院感染的主要来源，许多金黄色葡萄球菌菌株对常用抗生素具有抗药性。比较基因组学分析和基因重要性研究表明，NADD家族的烟酸单核苷酸(NaMN)腺基转移酶是大多数细菌(包括金黄色葡萄球菌)NAD生物发生中不可缺少的关键酶，是开发新型抗菌药物的重要靶点。在以往的研究中，首先从具有代表性的革兰氏阳性和革兰氏阴性细菌中鉴定出NADD酶的小分子抑制剂，然后确认它们的靶向抗菌活性。部分化合物对金黄色葡萄球菌NADD酶也有较强的抑制活性。这些结果验证了NADD靶标，并为寻找亲和力、选择性和抗菌性能显著改善的新抑制剂奠定了基础。 拟议的项目将通过追求下列具体目标来实现这一目标：(1)筛选MLPCN小分子化合物文库，并进行HIT优化，以确定金黄色葡萄球菌NADD酶的高亲和力抑制剂(IC50 D1微米)；(2)通过二次检测和在抗菌药物的反筛选中进行确认的HITS，以确定该酶是功能上但结构上不同的人类酶；(3)评估所选提名探针的抗菌性能和动力学机制。建议项目的可行性得到了纯重组靶酶的可用性以及在初步研究中开发的HTS检测方法的支持。筛选出的最佳抑制剂将在未来的工作中作为分子探针，进一步探索NAD的生物合成，作为开发新型抗生素的靶途径。